The US healthcare conglomerate will slash up to 8,000 jobs. Unfortunately, the benefits are likely to be as fleeting as the cuts accompanying giant pharma mergers. That's because it's increasingly tough finding new drugs to replace lost revenue as sales of old products run down.Sign up to read the rest of this subscriber-only content, or if you are already a member please sign in here.
Forgotten your password? Get a password reminder.
This Views Flash will shortly be followed by a Considered View